文献速递临床试验与 GCP

早期经鼻高流量氧疗与标准氧疗对急性低氧性呼吸衰竭住院患儿住院时长的影响:PARIS-2随机临床试验

Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项在澳大利亚和新西兰14家医院开展的多中心随机临床试验纳入1567例1至4岁急性低氧性呼吸衰竭患儿,1:1随机分配至高流量氧疗组(753例)或标准氧疗组(764例)。主要结局住院时长在高流量氧疗组反而更长(中位1.77天 vs 1.50天;校正风险比0.83,95%CI 0.75-0.92;P<.001)。结论认为,以经鼻高流量氧疗作为初始主要治疗并未显著缩短住院时长。

要点

  • 高流量氧疗组住院时长中位1.77天,标准氧疗组1.50天,高流量组更长(校正风险比0.83,95%CI 0.75-0.92;P<.001)。
  • 高流量氧疗组氧疗时长中位1.07天 vs 标准氧疗组0.75天(校正风险比0.78,95%CI 0.70-0.86)。
  • 高流量氧疗组入住ICU 94例(12.5%)vs 标准氧疗组53例(6.9%)(校正比值比1.93,95%CI 1.35-2.75)。

核心结论

  • 在1至4岁急性低氧性呼吸衰竭患儿中,以经鼻高流量氧疗作为初始主要治疗,与标准氧疗相比未显著缩短住院时长。

研究设计与样本

  • 多中心随机临床试验,在澳大利亚和新西兰14家城市及三级医院开展。
  • 纳入1567例1至4岁因急性低氧性呼吸衰竭需住院的儿童,2017年12月18日至2020年3月18日随机分组,末例随访于2020年3月22日完成。
  • 患儿按1:1随机分配至经鼻高流量氧疗组(n=753)或标准氧疗组(n=764);氧疗类型无法设盲,但研究者在结局数据锁定前保持盲态。
  • 主要分析纳入1517例(97%),中位年龄1.9岁(IQR 1.4-3.0岁),女性732例(46.7%),全部患儿完成试验。

主要发现

  • 主要结局住院时长在高流量氧疗组显著更长:中位1.77天(IQR 1.03-2.80天)vs 标准氧疗组1.50天(IQR 0.85-2.44天),校正风险比0.83(95%CI 0.75-0.92),P<.001。
  • 9项预设次要结局中有4项无显著差异。
  • 氧疗时长中位1.07天(IQR 0.50-2.06天)vs 标准氧疗组0.75天(IQR 0.35-1.61天),校正风险比0.78(95%CI 0.70-0.86)。
  • 入住ICU:高流量氧疗组94例(12.5%)vs 标准氧疗组53例(6.9%),校正比值比1.93(95%CI 1.35-2.75)。
  • 仅1例死亡,发生于高流量氧疗组。

局限性

  • 氧疗类型无法设盲。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nasal high-flow oxygen therapy in infants with bronchiolitis and hypoxia has been shown to reduce the requirement to escalate care. The efficacy of high-flow oxygen therapy in children aged 1 to 4 years with acute hypoxemic respiratory failure without bronchiolitis is unknown. OBJECTIVE: To determine the effect of early high-flow oxygen therapy vs standard oxygen therapy in children with acute hypoxemic respiratory failure. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized clinical trial was conducted at 14 metropolitan and tertiary hospitals in Australia and New Zealand, including 1567 children aged 1 to 4 years (randomized between December 18, 2017, and March 18, 2020) requiring hospital admission for acute hypoxemic respiratory failure. The last participant follow-up was completed on March 22, 2020. INTERVENTIONS: Enrolled children were randomly allocated 1:1 to high-flow oxygen therapy (n = 753) or standard oxygen therapy (n = 764). The type of oxygen therapy could not be masked, but the investigators remained blinded until the outcome data were locked. MAIN OUTCOMES AND MEASURES: The primary outcome was length of hospital stay with the hypothesis that high-flow oxygen therapy reduces length of stay. There were 9 secondary outcomes, including length of oxygen therapy and admission to the intensive care unit. Children were analyzed according to their randomization group. RESULTS: Of the 1567 children who were randomized, 1517 (97%) were included in the primary analysis (median age, 1.9 years [IQR, 1.4-3.0 years]; 732 [46.7%] were female) and all children completed the trial. The length of hospital stay was significantly longer in the high-flow oxygen group with a median of 1.77 days (IQR, 1.03-2.80 days) vs 1.50 days (IQR, 0.85-2.44 days) in the standard oxygen group (adjusted hazard ratio, 0.83 [95% CI, 0.75-0.92]; P < .001). Of the 9 prespecified secondary outcomes, 4 showed no significant difference. The median length of oxygen therapy was 1.07 days (IQR, 0.50-2.06 days) in the high-flow oxygen group vs 0.75 days (IQR, 0.35-1.61 days) in the standard oxygen therapy group (adjusted hazard ratio, 0.78 [95% CI, 0.70-0.86]). In the high-flow oxygen group, there were 94 admissions (12.5%) to the intensive care unit compared with 53 admissions (6.9%) in the standard oxygen group (adjusted odds ratio, 1.93 [95% CI, 1.35-2.75]). There was only 1 death and it occurred in the high-flow oxygen group. CONCLUSIONS AND RELEVANCE: Nasal high-flow oxygen used as the initial primary therapy in children aged 1 to 4 years with acute hypoxemic respiratory failure did not significantly reduce the length of hospital stay compared with standard oxygen therapy. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12618000210279.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Franklin D, Babl FE, George S, et al. Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial. JAMA. 2023. PMID: 36648469. doi:10.1001/jama.2022.21805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。